American Association for Cancer Research (AACR) 2021

A novel circulating tumor DNA (ctDNA) assay enables monitoring of disease progression and treatment response in disseminated preclinical hematologic cancer models

Combination activity of acalabrutinib (BTKi) and capivasertib (AKTi) in diffuse large B-cell lymphoma

Discovery and first structural disclosure of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper

In vitro cellular profiling of AZD5305, novel PARP1-selective inhibitor and trapper

Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper

The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models

The novel PARP1-selective inhibitor AZD5305 has reduced haematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D

Tumor response and MET-detection methods: exploratory biomarker analysis of Part B of the Phase 1b TATTON study

Pooled Analysis of Drug-Related Interstitial Lung Disease in 8 Single-Arm Trastuzumab Deruxtecan Studies